Stocks›Healthcare›RGEN

RGEN

REPLIGEN CORP
NasdaqResearch view
$189.68−0.51%
Sep 25 close · 1D EOD · Databento
HealthcareBiological Products, (No Diagnostic Substances)Large-capSEC EDGAR FY 2025-12-31

The numbers · FY2025, filed

SEC EDGAR
Market cap$10.7B
Revenue$738.3M+16.40%
Net income$48.9M
EPS, diluted$0.86+287.00%
Operating margin7.5%
Return on equity2.3%
All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31
SectorHealthcare
Market Cap$10.7B
Enterprise Value$10.7B
Income$48.9M
Sales$738.3M
Book/sh$37.32
Cash/sh$10.03
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio7.12
Current Ratio8.37
Debt/Eq0.26
EPS (ttm)$0.86
EPS this Y287.0%
EPS past 3/5Y-35.7%
Sales past 3/5Y-2.7%
EPS Y/Y TTM287.0%
Sales Y/Y TTM16.4%
Shs Outstand56.44M
ROA1.7%
ROE2.3%
ROIC2.1%
Gross Margin—
Oper. Margin7.5%
Profit Margin6.6%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$670.5M
FY21
$801.5M
FY22
$632.4M
FY23
$634.4M
FY24
$738.3M
FY25

Operating leverage — margins

GrossOperatingNet
0%40%80%7%7%FY21FY22FY23FY24FY25
Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it
USDFY2021FY2022FY2023FY2024FY2025

Same industry

In the screener →

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.